Home World News PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC... World News PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 274 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab February 4, 2021 Brothers Break Down After Seeing Their Parents For First Time In... October 31, 2021 Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... May 17, 2024 New Task Force Focuses on Quality of Life for AYAs with... August 4, 2021 Load more HOT NEWS The Power of Fruits and Vegetables Contraception and cancer – a look behind the headlines Celebrating 10 years of partnership with ScottishPower and £35m raised Real-World Patients with Cancer Show Lower Survival Times and Treatment-Associated Survival...
